case based panel discussion stage 3 nsclc - tumor mutational burden (tmb), the value in testing
Published 4 years ago • 90 plays • Length 5:26Download video MP4
Download video MP3
Similar videos
-
10:08
case based panel discussion stage 3 nsclc - does timing of treatment make a difference in response.
-
6:23
unresectable nsclc - tumor mutational burden (tmb), the value in testing
-
4:34
case based panel discussion - stage 3 nsclc treatment standard and the risk of potential pneumonitis
-
8:16
case based panel discussion - stage 3 nsclc best schedule - durvalumab/imfinzi in varying patients
-
11:27
case based panel discussion - stage 3 nsclc, frail patient competing risks, best treatment approach?
-
7:44
treatment for kras g12c mutated nsclc with high tumor mutational burden -case-based panel discussion
-
11:25
case based panel discussion - stage3 nsclc should we do molecular tests? effect treatment decision?
-
5:17
immunotherapy in stage iii nsclc - case based panel discussion
-
6:30
stage 3 squamous lung cancer with low pd-l1 - case based panel discussion
-
3:48
treating stage iii nsclc - case based panel discussion
-
9:04
case based panel discussion - stage3 nsclc - checkmate 227 immuno combo, another treatment option?
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
12:59
case based panel discussion - adv non squamous nsclc, low pd-l1 no mutation - best systemic therapy?
-
6:15
treatment options for egfr nsclc - case based panel discussion
-
13:00
stage 3a node-positive lung adenocarcinoma with alk rearrangement - case based panel discussions
-
5:39
non-bulky nsclc 2b disease: the role of chemoimmunotherapy - case based panel discussion
-
6:17
case based panel discussion - stage 3 nsclc - patients with pdl1 - 0, is immunotherapy beneficial?
-
3:56
surgical options for stage iv nsclc with brain metastases - case based panel discussion